Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

167.14 -0.13 (-0.08%)
Streaming Delayed Price Updated: 2:39 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Insulet Corp

< Previous 1 2 3 4 5 6 Next >
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs
7 Stable Stocks for 50% Returns by Early 2025
These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries. 
Via InvestorPlace
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Over the past 12 months, 10 Large-Cap stocks have underperformed all others. 
Via Talk Markets
5 Stocks To Buy On The Dip To Gain From The Wall Street Rally
Wall Street had a dream run in 2023, reversing the nightmare of 2022. The impressive bull run appears set to continue in 2024. Thus, here is a look at some stocks that may be worth buying on the dip... 
Via Talk Markets
Analyst Scoreboard: 5 Ratings For Insulet
Via Benzinga
Insulet: Q4 Earnings Insights
Via Benzinga
Should you consider NASDAQ:PODD for growth investing?
Exploring INSULET CORP (NASDAQ:PODD)'s growth characteristics. 
Via Chartmill
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Is It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?
A handful of large-cap stocks are now on sale. The discount, however, doesn't necessarily make them worth buying. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. 
Via Benzinga
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak... 
Via Benzinga
Topics Stocks
Exposures US Equities
INSULET CORP (NASDAQ:PODD) is a candidate for growth investors. Here's why.
Exploring growth characteristics of INSULET CORP (NASDAQ:PODD). 
Via Chartmill
Expert Ratings For Insulet
Via Benzinga
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
Nasdaq, S&P 500 Set for Mixed Open After Nvidia Euphoria: Analyst Picks Major Market Catalyst This Year If There Are No Rate Cuts
After the exuberance seen on Thursday, investors may assess whether it was an irrational one, and futures trading on Friday reflects edginess. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
Market participants remain attentive to several factors shaping the day's trading landscape, including scheduled Fed speeches, weekly jobless claims data, and private-sector activity readings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Should you consider NASDAQ:PODD for growth investing?
Exploring growth characteristics of INSULET CORP (NASDAQ:PODD). 
Via Chartmill
What 8 Analyst Ratings Have To Say About Insulet
Via Benzinga
Top Stock Picks For Week Of December 25, 2023
MoneyLion Inc. is a data-driven, digital financial platform. Insulet Corporation is a leading developer, manufacturer, and marketer of the Omnipod Insulin Management System. 
Via Talk Markets
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Should you consider NASDAQ:PODD for growth investing?
Why INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why the growth investor may take a look at NASDAQ:PODD.
INSULET CORP (NASDAQ:PODD) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
What Stocks Drove The Recent Record Rally? A Breakdown You Can't Miss
The technology sector has done well during the recent stock market rally as seen in indices such as Nasdaq 100 and S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Insulet Surges After Eye-Popping Earnings Growth Wallops Expectations
Insulet makes an insulin pump called Omnipod. U.S. sales are on the rise. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.